Babban Rage Nauyi akan Haɗin Tirzepatide zuwa Abubuwa Bakwai

Daga cikin mutane 3188 da ke da nau'in ciwon sukari na 2 waɗanda ke bin tsarin tirzepatide (Mounjaro, Lilly) a cikin gwaje-gwaje masu mahimmanci guda huɗu na wakili, kwata ya sami aƙalla 15% yanke daga nauyin jikinsu na asali bayan makonni 40-42 na jiyya. kuma masu bincike sun samo asali guda bakwai masu mahimmanci waɗanda ke da alaƙa da mahimmanci tare da mafi girma na wannan matakin asarar nauyi.

"Wadannan binciken suna taimakawa wajen sanar da mutanen da ke da nau'in ciwon sukari na 2 sun fi dacewa su sami raguwar nauyin jiki mafi girma tare da ingantattun abubuwan haɗari na cardiometabolic tare da tirzepatide," in ji marubutan.

HANYA:

• Masu binciken sun gudanar da nazarin bayanan da aka tattara daga jimillar mutane 3188 da ke da nau'in ciwon sukari na 2 waɗanda suka kasance masu bin tsarin tirzepatide da aka ba su na tsawon makonni 40-42 a cikin kowane ɗayan gwaji huɗu masu mahimmanci na wakili: SURPASS-1, SURPASS- 2, SURPASS-3, da SURPASS-4.
• Masu binciken sun yi niyya ne don gano masu hasashen raguwar nauyin jikin aƙalla 15% tare da maganin tirzepatide a kowane ɗayan allurai uku da aka gwada - 5 MG, 10 MG, ko 15 mg - waɗanda aka yi ta allurar subcutaneous sau ɗaya a mako.
• Dukkanin gwaje-gwaje guda hudu da suka ba da bayanai sun haramta magani na lokaci guda wanda zai inganta asarar nauyi, kuma mutanen da aka haɗa a cikin bincike ba su karbi magungunan ceto don sarrafa glycemia ba.
• Ma'aunin inganci na farko a cikin duk karatun huɗun shine ikon tirzepatide don haɓaka sarrafa glycemic (wanda aka auna ta matakin A1c) idan aka kwatanta da placebo, semaglutide (Ozempic) 1 mg SC sau ɗaya a mako, insulin degludec (Tresiba, Novo Nordisk), ko insulin glargine. Basaglar, Lilly).

TAKEWA:

• Daga cikin mutanen 3188 da suka kasance masu bin tsarin tirzepatide na tsawon makonni 40-42, 792 (25%) sun sami raguwar nauyi na akalla 15% daga asali.
• Multivariate bincike na asali covariates ya nuna cewa waɗannan abubuwa bakwai suna da alaƙa da mahimmanci tare da asarar nauyi ≥15%: mafi girman adadin tirzepatide, kasancewar mace, kasancewar launin fari ko Asiya, kasancewar ƙarami, yin jiyya tare da metformin, samun ingantaccen sarrafa glycemic (tushen. a kan ƙananan A1c da ƙananan glucose na jini mai azumi), da samun ƙananan matakan lipoprotein cholesterol mara nauyi.
• Yayin da ake biyo baya, nasarar da aka samu aƙalla raguwar kashi 15% a cikin ma'aunin nauyi na asali yana da alaƙa da haɓaka mafi girma a cikin A1c, matakin glucose mai azumi, kewayen kugu, hawan jini, matakin ƙwayar triglyceride, da matakin ƙwayar hanta enzyme alanine transaminase. .
  

  A CIKIN AIKI:

  "Wadannan binciken na iya ba da bayanai masu mahimmanci ga likitocin da masu fama da ciwon sukari na 2 game da yiwuwar samun raguwar nauyin jiki mai yawa tare da tirzepatide, kuma suna taimakawa wajen nuna alamun ci gaba da za a iya gani a cikin kewayon haɗarin cardiometabolic tare da tirzepatide-induced nauyi asara. ” Marubutan sun kammala a cikin rahoton nasu.